AFT Pharmaceuticals hits $200m revenue milestone despite profit dip

AFT Pharmaceuticals hits $200m revenue milestone despite profit dip
AFT co-founder Dr Hartley Atkinson says launching into new markets takes time to reap rewards. (Image: AFT Pharmaceuticals)
Rebecca Stevenson
AFT Pharmaceuticals' co-founder, Dr Hartley Atkinson, says the firm’s choice to invest in Australia has been vindicated. The dual-listed pharmaceutical company released its results for the year ended March 31 on Thursday. While profit after tax fell to $11.9 million, revenue cracked $200m for the first time. Revenue from Australia increased by 17% to $127.1m, and operating profit leapt 65% to $25.5m. Chief executive Atkinson said AFT's investment in Australia had caused some concern, but the result proved its strate...

More Markets

Caniwi's Bowker sells NZME stake
Markets

Caniwi's Bowker sells NZME stake

The investor said he's made a good return. 

Golden visas could increase M&A flow
Markets

Golden visas could increase M&A flow

Despite Liberation Day wobbles, US buyers are active and hunting NZ firms.

Napier Port buoyant as NZ sharemarket rises
Markets Market Close

Napier Port buoyant as NZ sharemarket rises

Napier Port announced strong earnings growth for the six months to March.

Tom Raynel 21 May 2025